Imugene (ASX:IMU) received clearance from the Cohort Review Committee to escalate the dose level in the intravenous combination segment of its phase one onCARlytics trial, targeting adult patients with advanced or metastatic solid tumors, according to a Thursday Australian bourse filing.
The trial seeks to evaluate the safety and efficacy of different routes of administration, intratumoral injection, and intravenous infusion of either onCARlytics, a CD19-expressing oncolytic virus, alone, or in combination with CD19-targeting bispecific monoclonal antibody blinatumomab, which is a cancer immunotherapy.
The IV combination arm will progress to a higher dose level after the completion of the safety observation period.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。